Free Trial

Oncobiologics (OTLK) Competitors

Oncobiologics logo
$1.39 +0.09 (+6.92%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$1.38 0.00 (-0.36%)
As of 10/24/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OTLK vs. CABA, CRBU, VOR, TRDA, EPRX, BDTX, PYXS, GNFT, ACRS, and TARA

Should you be buying Oncobiologics stock or one of its competitors? The main competitors of Oncobiologics include Cabaletta Bio (CABA), Caribou Biosciences (CRBU), Vor Biopharma (VOR), Entrada Therapeutics (TRDA), Eupraxia Pharmaceuticals (EPRX), Black Diamond Therapeutics (BDTX), Pyxis Oncology (PYXS), GENFIT (GNFT), Aclaris Therapeutics (ACRS), and Protara Therapeutics (TARA). These companies are all part of the "pharmaceutical products" industry.

Oncobiologics vs. Its Competitors

Oncobiologics (NASDAQ:OTLK) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

Oncobiologics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OncobiologicsN/AN/A-$75.37M-$0.57-2.44
Cabaletta BioN/AN/A-$115.86M-$2.71-0.91

In the previous week, Cabaletta Bio had 6 more articles in the media than Oncobiologics. MarketBeat recorded 7 mentions for Cabaletta Bio and 1 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 1.62 beat Cabaletta Bio's score of 0.50 indicating that Oncobiologics is being referred to more favorably in the media.

Company Overall Sentiment
Oncobiologics Very Positive
Cabaletta Bio Positive

Oncobiologics has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Cabaletta Bio has a beta of 3.01, meaning that its share price is 201% more volatile than the S&P 500.

Oncobiologics' return on equity of 0.00% beat Cabaletta Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
OncobiologicsN/A N/A -332.30%
Cabaletta Bio N/A -92.11%-74.08%

11.2% of Oncobiologics shares are owned by institutional investors. 4.8% of Oncobiologics shares are owned by company insiders. Comparatively, 11.3% of Cabaletta Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Oncobiologics presently has a consensus price target of $7.00, indicating a potential upside of 403.60%. Cabaletta Bio has a consensus price target of $13.44, indicating a potential upside of 444.31%. Given Cabaletta Bio's stronger consensus rating and higher possible upside, analysts plainly believe Cabaletta Bio is more favorable than Oncobiologics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncobiologics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14
Cabaletta Bio
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82

Summary

Cabaletta Bio beats Oncobiologics on 9 of the 14 factors compared between the two stocks.

Get Oncobiologics News Delivered to You Automatically

Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OTLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OTLK vs. The Competition

MetricOncobiologicsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$61.74M$3.46B$6.21B$10.81B
Dividend YieldN/A2.28%5.72%4.80%
P/E Ratio-2.4428.5131.6030.99
Price / SalesN/A497.40595.06133.64
Price / CashN/A46.9537.2561.86
Price / Book-0.4510.4012.056.61
Net Income-$75.37M-$52.83M$3.34B$277.10M
7 Day Performance6.11%2.10%1.94%2.57%
1 Month Performance43.28%10.17%6.88%3.20%
1 Year Performance-74.45%16.57%56.06%33.22%

Oncobiologics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OTLK
Oncobiologics
2.8171 of 5 stars
$1.39
+6.9%
$7.00
+403.6%
-74.4%$61.74MN/A-2.4420Positive News
CABA
Cabaletta Bio
2.7396 of 5 stars
$2.49
+7.3%
$13.44
+439.9%
-36.8%$227.75MN/A-0.9250Analyst Forecast
High Trading Volume
CRBU
Caribou Biosciences
2.6314 of 5 stars
$2.38
-4.4%
$6.67
+180.1%
+40.7%$221.63M$9.99M-1.34100News Coverage
Positive News
Analyst Forecast
VOR
Vor Biopharma
2.5118 of 5 stars
$32.29
+3.4%
$113.83
+252.5%
N/A$221.32MN/A-0.12140Analyst Forecast
Insider Trade
TRDA
Entrada Therapeutics
3.3953 of 5 stars
$5.81
-4.6%
$25.67
+341.8%
-59.8%$221.01M$210.78M-3.26110News Coverage
Analyst Forecast
EPRX
Eupraxia Pharmaceuticals
2.8565 of 5 stars
$6.05
-0.3%
$11.00
+81.8%
+112.0%$217.56MN/A-7.1229Analyst Forecast
Short Interest ↑
BDTX
Black Diamond Therapeutics
3.8734 of 5 stars
$3.80
-7.1%
$11.00
+189.5%
+31.9%$216.35M$70M16.5290Positive News
Analyst Forecast
PYXS
Pyxis Oncology
2.8863 of 5 stars
$3.45
-6.8%
$7.75
+124.6%
-5.5%$213.97M$16.15M-2.1660Analyst Forecast
High Trading Volume
GNFT
GENFIT
2.0781 of 5 stars
$4.25
flat
$7.00
+64.7%
-22.1%$212.51M$41.52M0.00120Positive News
Gap Down
ACRS
Aclaris Therapeutics
2.5193 of 5 stars
$1.91
+2.1%
$8.71
+356.2%
+27.2%$206.91M$16.79M-1.39100Positive News
TARA
Protara Therapeutics
1.8112 of 5 stars
$5.34
+2.3%
$19.60
+267.0%
+125.7%$206.03MN/A-3.3030News Coverage
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:OTLK) was last updated on 10/26/2025 by MarketBeat.com Staff
From Our Partners